Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-04-11 00:00:00 ET · period of report 2022-04-07 · accession 0001708138-22-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-11 | 2022-04-07 | REGN | LAROSA JOSEPH J | EVP GC, Secret | S - Sale | $721.10 | -5,114 | 16.9K | -23% | -$3.69M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-07 | S | D | 5,114 | $721.10 | 16,900 | D | — | — | (F2) Represents volume-weighted average price of sales of 5,114 shares of Company stock on April 7, 2022 at prices ranging from $721.10 to $721.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 7, 2022 at each separate price. |